A study showed that knockdown of DDR2 in the NA13 cell line, B16F10 cell line and mammary tumor cell line E0771 could enhance the sensitivity of tumor cells to anti-PD-1 therapy in vitro. The gene discussed is DDR2; the disease is neoplasm.